Cannabis may give modest relief from some neuropathic pain, but the evidence is mixed: small trials in HIV and diabetic neuropathy found benefits, while the largest 2026 reviews found effects that were small, uncertain or not clinically meaningful. Results for chemotherapy-induced neuropathy have been mostly negative. Side effects such as dizziness and sleepiness are common.
Neuropathy is pain from damaged nerves, often described as burning, tingling, electric or pins and needles, usually in the feet and hands. Diabetes is the most common cause; HIV, chemotherapy, shingles and injury are others. Standard drugs help only some patients, which is why cannabis keeps coming up. This page replaces an old post about a Calgary THC study and covers what the trials actually show, as of October 2026.
Evidence at a Glance
| Claim | Evidence level | Source |
|---|---|---|
| Cannabis or cannabinoids relieve chronic pain in adults (all types) | Substantial (2017); later reviews find small effects | NASEM 2017 |
| Cannabis-based medicines give 50% relief of neuropathic pain | No clear evidence; very low certainty | Cochrane 2026 |
| THC-containing products slightly reduce chronic, mostly neuropathic pain | Low to moderate; small effect | Chou 2026, Annals of Internal Medicine |
| Smoked cannabis relieves HIV neuropathy pain | Limited; two small short trials positive | Abrams 2007, Ellis 2009 |
| Cannabinoids relieve diabetic neuropathy pain | Limited; four small trials, mostly positive | Sherman 2026 review |
| Cannabinoids relieve chemotherapy-induced neuropathy | Insufficient; no trial beat placebo | Datta 2026 review |
| CBD alone relieves neuropathic pain | No clear evidence | Cochrane 2026 |
Diabetic Neuropathy
The Calgary nabilone trial
The study in our original post came from the University of Calgary’s Department of Clinical Neurosciences and was published in Pain in 2012. It tested nabilone, a prescription synthetic form of THC, added to patients’ usual pain drugs. All 37 participants took nabilone for four weeks; the 26 who got at least 30% relief were then randomly assigned to keep taking it or switch to placebo for five more weeks. Those who stayed on nabilone had less pain than those switched to placebo, along with better sleep, less anxiety and better quality of life. The average dose at the end was 2.9 mg a day.
The design matters. Picking only early responders makes a drug look better than it would in an unselected group, and 11 of 37 patients did not respond at all. It was still a well-run trial, and it is one reason nabilone performs better than other THC products in reviews.
Inhaled cannabis
A 2015 University of California, San Diego crossover trial gave 16 people with treatment-resistant diabetic neuropathy single doses of vaporized cannabis at three strengths. Pain dropped in a dose-dependent way, but the high dose also impaired performance on two of three thinking tests. A 2026 systematic review found only four randomized trials in diabetic neuropathy; three were positive, but the authors said small size and risk of bias preclude firm conclusions. For more on cannabis and diabetes generally, see our diabetes research page.
HIV Neuropathy
Two trials from the University of California’s cannabis research center are still among the most cited:
- Abrams 2007, San Francisco: 50 patients smoked cannabis (3.56% THC) or placebo cigarettes three times a day for five days. Daily pain fell by a median 34% with cannabis versus 17% with placebo, and 52% versus 24% got at least 30% relief.
- Ellis 2009, San Diego: in a crossover trial with cannabis of 1% to 8% THC, 46% achieved at least 30% relief on cannabis versus 18% on placebo.
Both were small, lasted days rather than months, and used low-potency cannabis compared with what dispensaries sell today. See our HIV/AIDS research page for appetite and other uses.
Chemotherapy-Induced Neuropathy
Results here are disappointing. A 2014 pilot of nabiximols, a THC and CBD mouth spray, in 16 patients found no overall difference from placebo, though five people responded well. A 2026 systematic review found three randomized trials of nabiximols, oral CBD and topical CBD, with 68 participants total; none showed better pain relief than placebo. Several larger trials are under way.
What the Big Reviews Say
The 2026 Cochrane review pooled 21 trials with 2,187 people. It found no clear evidence that THC-dominant, balanced THC/CBD or CBD-dominant products help people reach 50% pain relief. Balanced THC/CBD products may slightly increase the number who feel “much improved,” but the reviewers judged the gain not clinically relevant, and nervous system side effects rose.
A 2026 review for the U.S. Agency for Healthcare Research and Quality, published in Annals of Internal Medicine, looked at 25 trials, 64% in neuropathic pain. THC-only and balanced products reduced pain by roughly half a point to three-quarters of a point on a 10-point scale, with more dizziness, sedation and nausea. Nabilone did better than dronabinol. Low-THC, high-CBD products did not appear to help.
The fair summary: some people get worthwhile relief, many do not, and on average the effect is small.
Risks and Side Effects
- Dizziness, sleepiness, confusion and nausea are the most common, and they increase with THC dose. Older adults with diabetes face added fall risk, and numb feet already raise that risk.
- Thinking and driving. Higher doses impaired performance on thinking tests in trials. Do not drive after using THC.
- Drug interactions. THC and CBD can add to the sedation of gabapentin, pregabalin and opioids, and CBD can inhibit liver enzymes that process many drugs, according to the National Cancer Institute.
- Dependence. NIDA notes that regular use can lead to cannabis use disorder.
- Smoking. Smoke irritates the lungs. Trials have used vaporized, oral and spray forms as alternatives. See our vaporizing guide for those risks.
Talk to Your Doctor
Neuropathy needs a diagnosis and treatment of its cause, especially blood sugar control in diabetes and foot checks to prevent ulcers. Ask your doctor whether a cannabinoid fits after first-line drugs, whether nabilone (a prescription option) is appropriate, how it interacts with your current medicines, and how to start with a low dose. Keep a pain diary so you can tell whether it is actually helping. More research summaries are in our cannabis research section.
Cannabis for Neuropathy FAQ
Does cannabis help nerve pain?
For some people, modestly. Small trials found relief in HIV and diabetic neuropathy, but large 2026 reviews found the average benefit small and uncertain.
Is CBD or THC better for neuropathy?
Products containing THC have the better evidence. CBD-dominant products have not clearly beaten placebo for neuropathic pain.
Does cannabis help chemotherapy neuropathy?
So far, no trial has shown it beats placebo. Evidence is insufficient to recommend it routinely.
What is nabilone?
A prescription synthetic cannabinoid similar to THC. In the U.S. it is approved for chemotherapy nausea and is sometimes prescribed off-label for pain.
Can I use cannabis with gabapentin?
Ask your doctor first. Both cause drowsiness and dizziness, and combining them can increase sedation and fall risk.
For adults 21+ in legal states. General information, not medical advice. Talk to a doctor before using cannabis for a health condition.
